Biodexa Pharmaceutical (NASDAQ: BDRX) The stock has shown significant volatility during today’s trading session, experiencing gains of nearly 150% at various points. Biodexa specializes in developing therapies for brain tumors.More importantly, the company I recently completed my registration Treatment phase of 9 children participating in a study on the lead asset, MTX110.
To help you better understand the company’s efforts to improve clinical outcomes for primary and metastatic brain tumors, I would like to briefly review this announcement.
Enter your email address in the box below to subscribe to Microcapdaily.com today.
About the MTX110 clinical trial:
of This particular study, enrolled children aged 4 to 17 years received radiotherapy according to standard medical practice. He then underwent surgery to implant a special catheter and programmable pump directly into the tumor. The purpose of this implant is to deliver a drug called MTX110 to the tumor site. Eight of nine patients received two injections of MTX110 via a technique called convection-enhanced delivery (CED), and different concentrations of the drug were tested.
An important update is that there were no reported serious side effects or toxicities associated with the use of MTX110 in this study. The drug is well tolerated by patients.
This study aims to evaluate the safety and efficacy of MTX110 in the treatment of children with DMG, a very difficult and life-threatening disease. DMG patients have very poor survival rates and current treatment options are limited. The results of the study, which is expected to be published in early 2024, will provide valuable information about the drug’s impact on disease.
Insights from private investors:
As mentioned earlier, microcap stocks often have a limited number of shares available and are commonly referred to as “tight” or “low” floats. For $BDRX these days Consolidated shares The stock fell below Nasdaq’s minimum bid compliance standards. This consolidation of shares was significant as it was conducted at a ratio of 80 He shares to 1 He share (1-80 shares) and will take effect on July 5, 2023. As a result, the number of shares available for trading decreased significantly and trading volatility increased significantly. . It’s worth noting that $BDRX’s free float is one of the lowest observed on NASDAQ. Only 220,22,000 shares available for trading. Many retail investors would consider this a “nanofloat”. Given this situation, it is understandable that such stocks can experience significant price volatility, attracting many investors looking for quick profits in short-term trading strategies.
$BDRX now.. 220k float last 4.95 https://t.co/w8aN576PGS
— Stephen Pfeffer (@sfef84) July 11, 2023
$BDRX It is one of the lowest floaters in existence today. I’m curious if they come for this. Then you may go crazy https://t.co/bHdhIQnqkA
— Zalmy (@greatstockpicks) July 11, 2023
Oh you have a post split pump $BDRX. Most of these have a front and rear split pump. Watch it all in a great sharing structure.
— Pronouns: you/stepmother (@MayaTrades) July 11, 2023
If $BDRX Volume up, this is going to explode
— stock stock (@stocksonstocks9) July 11, 2023
About diffuse midline glioma (DMG):
damage A type of brain tumor that forms in the central part of the brain. It cannot be surgically removed and primarily affects children. Average survival is about 9 to 11 months, and most patients die within 1 year of diagnosis. Current treatments, such as chemotherapy, are not very effective because the drugs have difficulty reaching the brain. About 1,100 people worldwide are diagnosed with his DMG each year.
About the MTX110:
MTX110 It is a modified version of a drug called panobinostat. It is designed to bypass the blood-brain barrier and be delivered directly to the tumor site through a catheter system. This allows high concentrations of drugs to be delivered to tumors with minimal side effects. MTX110 is being studied for efficacy in the treatment of recurrent glioblastoma, pediatric DMG, and recurrent medulloblastoma. Previous studies have shown promising results in clinical trials using DMG and glioblastoma cells.
About the Phase 1 clinical trial:
The primary objective of phase 1 clinical trials is to evaluate the safety and tolerability of new drugs or treatments in small groups of participants. Phase 1 trials are the early stages of human trials and typically involve a relatively small number of healthy volunteers or patients. The main objectives of the Phase 1 trial are to:
safety: Phase 1 trials are designed to identify potential treatment-related side effects or side effects. Researchers will closely monitor participants for adverse effects and determine acceptable dose levels.
Dosage determination: These studies will help determine an appropriate dose range for further study. Researchers will give participants different doses to assess the drug’s pharmacokinetics (how the drug is absorbed, distributed, metabolized and excreted in the body) and to determine the optimal dose for further study. may be administered.
Pharmacokinetics and Pharmacodynamics: Phase 1 trials evaluate how drugs are processed in the body, including absorption, distribution, metabolism and excretion. It also evaluates how drugs interact with the body’s cells and affect target diseases and conditions.
Preliminary effectiveness: Phase 1 trials are primarily focused on safety, but may also provide early data on treatment efficacy. Researchers can assess early signs of efficacy and measure biomarkers to determine if a drug is having the desired effect.
Overall, the primary objectives of a Phase 1 clinical trial are to gather important information about a drug’s safety profile, establish an appropriate dose range, and identify the next phase (Phase 2) to assess therapeutic efficacy. to lay the foundation for further research in Phase 3 and Phase 3). and potential benefits.
Conclusion:
Biodexa Inc. (NASDAQ: BDRX) has achieved another important milestone with its flagship asset, the MTX110. Due to the limited number of shares available after a stock split, stock prices move rapidly, attracting investors looking for quick returns from potentially large gains. According to them presentation deck, There are several important milestones and catalysts to watch over the coming months. These include release of Phase 1 data at DMG, submission of a Phase 2 IND at DMG, publication of PFS data from MAGIC-G1 study cohort A, and initiation of a Phase 2 trial at DMG.
We’ll keep you updated on BDRX as more details become available. Subscribe and follow us on Microcapdaily.
Disclosure: I received no compensation for this article/video. MicroCap Daily is not an investment advisor. This article/video does not provide investment advice. Always do your research and make your own investment decisions or consult your local financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold any securities. This article/video is our opinion and is for informational and educational purposes only and does not constitute investment advice. Past performance is not indicative of future performance.
Photo by Jarmoluk from Pixabay